Liraglutide Attenuates Diabetic Cardiomyopathy via the ILK/PI3K/AKT/PTEN Signaling Pathway in Rats with Streptozotocin-Induced Type 2 Diabetes Mellitus

• Main Authors: Shatha M. Alobaid (Author), Rahaf M. Alshahrani (Author), Asma S. Alonazi (Author), Nawal M. Alrasheed (Author), Maha A. Alamin (Author), Tahani K. Alshammari (Author), Anfal F. Bin Dayel (Author), Doaa M. Elnagar (Author), Rana R. Alotaibi (Author), Lama A. Almuthnabi (Author), Dalia H. Almasud (Author), Shahad E. Al-Ammar (Author), Shahad O. Almadhi (Author), Reema A. Almalke (Author), Nouf T. Aldamri (Author), Hanan K. Alghibiwi (Author), Dalal A. Alkhelb (Author), Nouf M. Alrasheed (Author)
• Format: Book
• Published: MDPI AG, 2024-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

One of the possible candidates for the treatment of diabetic cardiomyopathy is liraglutide, a glucagon-like peptide-1 receptor (GLP1R) agonist. In this study, the impacts of liraglutide on the integrin-linked kinase (ILK)-related PI3K/AKT axis in rats with type 2 diabetes induced via streptozotocin...